110 related articles for article (PubMed ID: 1753416)
1. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies.
Ohtsu T; Sai T; Oka M; Sugai Y; Tobinai K
Jpn J Clin Oncol; 1991 Oct; 21(5):360-5. PubMed ID: 1753416
[TBL] [Abstract][Full Text] [Related]
2. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.
Zuckerman E; Zuckerman T; Douer D; Qian D; Levine AM
Cancer; 1998 Sep; 83(6):1224-30. PubMed ID: 9740089
[TBL] [Abstract][Full Text] [Related]
3. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus infection in allogeneic bone marrow transplantation.
Ustün C; Koç H; Karayalcin S; Akyol G; Gürman G; Ilhan O; Akan H; Ozcan M; Arslan O; Konuk N; Uysal A; Beksaç M
Bone Marrow Transplant; 1997 Aug; 20(4):289-96. PubMed ID: 9285543
[TBL] [Abstract][Full Text] [Related]
10. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy.
Sekine R; Taketazu F; Kuroki M; Takagi S; Imawari M; Kanazawa Y; Kawakami M
Int J Hematol; 2000 Apr; 71(3):256-8. PubMed ID: 10846831
[TBL] [Abstract][Full Text] [Related]
11. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
12. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
13. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases.
Locasciulli A; Bacigalupo A; Van Lint MT; Chemello L; Pontisso P; Occhini D; Uderzo C; Shulman HM; Portmann B; Marmont AM
Bone Marrow Transplant; 1990 Jul; 6(1):25-9. PubMed ID: 2390630
[TBL] [Abstract][Full Text] [Related]
16. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.
Kim SG; Chun JM; Jin R; Kim JY; Won DI; Hwang YJ
Transplant Proc; 2010 Apr; 42(3):843-5. PubMed ID: 20430187
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.
el-Sayed MH; Shanab G; Karim AM; el-Tawil A; Black A; Dixon JS
Pediatr Hematol Oncol; 2004 Mar; 21(2):145-56. PubMed ID: 15160513
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours.
Alexopoulos CG; Vaslamatzis M; Hatzidimitriou G
Br J Cancer; 1999 Sep; 81(1):69-74. PubMed ID: 10487614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
